Cornerstone Pharmaceuticals Receives Funding through New Jersey's Technology Business Tax Certificate Transfer Program

CRANBURY, NEW JERSEY (January 21,2015) - Cornerstone  Pharmaceuticals,  Inc., a clinical
stage company and leader in the field of cancer metabolism-based therapeutics, today announced that it has  received funding through the State  of New Jersey's Business Tax Certificate Transfer Program for the year 2014. Read More >>

 

slider bt care differently

slider bt discovery

500 characters left
nysehome
videohome
videobutton

Know the Science behind

AEMD Platform
Read More >>
Slide item 1

Another Breakthrough
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Read More >>
Slide item 2

People behind the Success

Our Team
Read More >>
Slide item 3
announcement1
announcement2
announcement3